Their mission is to provide innovative solutions and therapies that address the needs of these patients. Led by an esteemed team of experts, jCyte is committed to making a difference in the field of ophthalmology. The leadership team includes John Sholar, the Chief Executive Officer, who brings over 25 years of experience in the biotech industry.

Henry J. Klassen, MD, PhD, the Co-founder and Chairman, is a renowned expert in neural plasticity and regeneration. His research has shown promising results in the improvement of photoreceptors in the degenerating retina.

Dr. Jing Yang, the Co-founder and Chief Science Officer, has more than 16 years of experience in ophthalmology. She has developed innovative techniques for isolating and growing retinal progenitor cells, which have potential applications in treating various optic nerve diseases.

With the expertise of their team and their dedication to finding effective solutions, jCyte is at the forefront of developing cell-based therapies for retinitis pigmentosa and other retinal disorders